Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 16 at 2:00 PM EDT

Register Free →

Pre-clinical Animal Study Execution

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This subcontract, titled Pre-clinical Animal Study Execution, involves conducting animal-based research for prime contractors supporting Department of Veterans Affairs kidney cancer projects. The scope of work includes managing animal species and strains, implementing randomization and blinding procedures to reduce bias, and executing experimental treatments. The provider is responsible for delivering raw experimental data, animal study reports, and validated endpoints while ensuring all activities adhere to IACUC approvals and Research Compliance standards for animals and human subjects. The opportunity is managed by the Defense Health Agency Contracting Activity under the Department of Defense, falling under NAICS code 541712. It was posted on June 18, 2026, with a response deadline of September 28, 2026.

General Info

Subcontract for pre-clinical kidney cancer animal research supporting Department of Veterans Affairs projects.

Agency

Department Of Defense → Defense Health Agency Contracting Activity - DhacaView Agency

NAICS

541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

This scope was carved out of HT942526KCRPIDA.

The full solicitation package (2 documents), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

DoW Kidney Cancer, Idea Development Award

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Defense → Defense Health Agency Contracting Activity - Dhaca
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department Of Defense → Defense Health Agency Contracting Activity - Dhaca
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Conducts animal-based research for prime contractors on Department of Veterans Affairs kidney cancer projects. Manages animal species and strains, implements randomization and blinding procedures to minimize bias, and executes experimental treatments. Requires IACUC approvals and compliance with Research Compliance (Animals and Human Subjects) standards. Delivers raw experimental data, animal study reports, and validated endpoints.

Similar Contracts

Same NAICS industry code

More opportunities from Department Of Defense → Defense Health Agency Contracting Activity - Dhaca

Same awarding agency

NAICS: 541715
New
Grant
DoW Breast Cancer, Breakthrough Award Levels 1 and 2
Solicitation # HT942526BCRPBTA122
The Department of Defense, through the Defense Health Agency Contracting Activity, is soliciting applications for the Fiscal Year 2026 Breast Cancer Research Program Breakthrough Award Levels 1 and 2 under solicitation number HT942526BCRPBTA122. This mechanism is designed to support high-potential research aimed at achieving breakthroughs in breast cancer, requiring all applications to address at least one overarching FY26 BCRP challenge or provide a strong justification for an exception. The program offers two funding levels with distinct research scopes, including a Population Science Studies option under Level 2 that may allow for increased funding and an extended period of performance. Eligible applicants may apply as a single Principal Investigator or through a partnering arrangement involving an Initiating PI and a Partnering PI. The application process follows a two-step sequence, with pre-applications due by November 4, 2026, and full applications due by November 18, 2026. For those utilizing the Partnering PI Option, both investigators must submit full applications to avoid administrative withdrawal. The program emphasizes a focus on research that can lead to clinical application and major impact, with all submissions governed by specific registration and review criteria managed by the grantor.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

4 days ago

DEADLINE

in 2 months
View Details